IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy

Journal of Clinical Gastroenterology

Volumn 43, Issue 3, 2009, Pages 272-279

  Montoliu, Carmina ^a   Piedrafita, Blanca ^b   Serra, Miguel A ^a   Del Olmo, Juan A ^a   Urios, Amparo ^b   Rodrigo, Jose M ^a   Felipo, Vicente ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

IL 18; IL 6; Minimal hepatic encephalopathy

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; FEMALE; GOLD STANDARD; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLICKER FUSION; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; INTERLEUKIN-18; INTERLEUKIN-6; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS;

EID: 67650863436     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31815e7f58     Document Type: Article

References (27)

1. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890-895. (Pubitemid 29248991)
2. Hui AY, Chan HL, Leung NW, et al. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol. 2002;34:569-572.
3. Amodio P, Montagnese S, Gatta A, et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004; 19:253-267.
4. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis and quantification: final report of the working party at the 11Word Congress of gastroenterology, Viena, 1998. Hepatology. 2002;35:716-721.
5. Romero-Gómez M, Boza F, Garcia Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96: 2718-2723. (Pubitemid 32889211)
6. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16:531-535. (Pubitemid 34188860)
7. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998; 28:45-49. (Pubitemid 28299984)
8. Wein C, Koch H, Popp B, et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39: 739-745. (Pubitemid 38337653)
9. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35:357-366. (Pubitemid 34106375)
10. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal antiinflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004;23:159-169. (Pubitemid 38980441)
11. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20:5709-5714. (Pubitemid 30636898)
12. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22:983-991. (Pubitemid 34066567)
13. Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003;134:142-150. (Pubitemid 36054172)
14. Weaver JD, Huang MH, Albert M, et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371-378. (Pubitemid 34857929)
15. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76-80. (Pubitemid 36818750)
16. Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247-254. (Pubitemid 38115829)
17. Odeh M, Sabo E, Srugo I, et al. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int. 2004;24:110-116. (Pubitemid 38584996)
18. Odeh M, Sabo E, Srugo I, et al. Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med. 2005;37: 603-612. (Pubitemid 41780148)
19. Verdon CP, Burton BA, Prior RL. Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal Biochem. 1995;224:502-508.
20. Daniluk J, Szuster-Ciesielska A, Drabko J, et al. Serum cytokine levels in alcohol-related liver cirrhosis. Alcohol. 2001; 23:29-34. (Pubitemid 32224861)
21. Marini JC, Broussard SR. Hyperammonemia increases sensitivity to LPS. Mol Genet Metab. 2006;88:131-137.
22. Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 1999;94:169-177. (Pubitemid 29063463)
23. Wiesner R, Eduards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donors livers. Gastroenterology. 2003;124:91-96. (Pubitemid 36055342)
24. Krabbe KS, Reichenberg A, Yirmiya R, et al. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun. 2005;19:453-460. (Pubitemid 41074784)
25. Harding D, Brull D, Humphries SE, et al. Variation in the interleukin-6 gene is associated with impaired cognitive development in children born prematurely: a preliminary study. Pediatr Res. 2005;58:117-120. (Pubitemid 40967440)
26. Nelson TE, Netzeband JG, Gruol DL. Chronic interleukin-6 exposure alters metabotropic glutamate receptor-activated calcium signalling in cerebellar Purkinje neurons. Eur J Neurosci. 2004;20:2387-2400.
27. Curran B, O'Connor JJ. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience. 2001;108:83-90. (Pubitemid 33152983)